<DOC>
	<DOCNO>NCT00528606</DOCNO>
	<brief_summary>This Phase 3 , double-blind , randomize , placebo-controlled study conduct United States . Subjects diagnosis Dupuytren 's contracture metacarpophalangeal ( MP ) proximal interphalangeal ( PIP ) joint result fixed flexion deformity least one finger , thumb , least 20° measured finger goniometry suitable injection randomize 2:1 receive AA4500 0.58 mg placebo . This study design part large clinical program , adult patient Dupuytren 's contracture palpable cord , data 2 pivotal Placebo-Controlled study ( AUX-CC-857 ( NCT00528606 ) AUX-CC-859 ( NCT00533273 ) ) 7 non-pivotal study evaluate .</brief_summary>
	<brief_title>AA4500 ( XIAFLEX™ , Proposed Name ) Treatment Dupuytren 's Contracture</brief_title>
	<detailed_description />
	<mesh_term>Contracture</mesh_term>
	<mesh_term>Dupuytren Contracture</mesh_term>
	<criteria>Subjects diagnosis Dupuytren 's contracture , fix flexion deformity least one finger , thumb , contracture least 20° , great 100° , MP ( 80° PIP ) joint , cause palpable cord never treat AA4500 . Had positive `` table top test , '' define inability simultaneously place affect finger ( ) palm flat table top . Judged good health . Had chronic muscular , neurological , neuromuscular disorder affect hand . Had receive treatment Dupuytren 's contracture , include surgery ( fasciectomy surgical fasciotomy ) , needle aponeurotomy/fasciotomy , injection verapamil and/or interferon select primary joint within 90 day first dose study drug . Had know recent history stroke , bleeding , disease process affect hand , medical condition , investigator 's opinion , would make subject unsuitable enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>